Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Cabozantinib |
| Synonyms | |
| Therapy Description |
Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cabozantinib | Cometriq | Cabometyx|Cabozantinib-s-malate|XL184 | AXL Inhibitor 30 FLT3 Inhibitor 66 KIT Inhibitor 57 MET Inhibitor 59 RET Inhibitor 52 ROS1 Inhibitor 20 VEGFR2 Inhibitor 37 | Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | Advanced Solid Tumor | predicted - sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) in culture (PMID: 21926191). | 21926191 |
| KIT N655K | Advanced Solid Tumor | decreased response | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT N655K demonstrated a reduced response to Cometriq (Cabometyx, cabozantinib) treatment compared to cells expressing KIT T670I in culture (PMID: 33212994). | 33212994 |
| KIT K558_G565delinsR | gastrointestinal stromal tumor | sensitive | Cabozantinib | Preclinical - Pdx | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) treatment resulted in tumor regression, decreased mitotic activity, and increased apoptotic activity in a gastrointestinal stromal tumor patient-derived xenograft (PDX) model harboring KIT K558_G565delinsR (PMID: 27777285). | 27777285 |
| RET rearrange | lung adenocarcinoma | predicted - sensitive | Cabozantinib | Phase II | Actionable | In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung adenocarcinoma, with a median duration of response of 7.0 months (PMID: 27825636; NCT01639508). | 27825636 |
| RET C634W | thyroid gland carcinoma | sensitive | Cabozantinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946). | 23705946 |
| RET mutant | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Phase III | Actionable | In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386). | 27525386 |
| RET M918T | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Guideline | Actionable | Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RET M918T (PMID: 31549998, PMID: 35491008; ESMO.org). | 31549998 detail... 35491008 |
| RET M918T | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Phase III | Actionable | In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386). | 27525386 |
| RET M918T | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Phase III | Actionable | In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012). | detail... |
| RET M918T | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Case Reports/Case Series | Actionable | In a clinical case study, Cometriq (cabozantinib) treatment resulted in a partial response in a patient with medullary thyroid carcinoma with extensive CNS metastasis harboring RET M918T, although the patient experienced multiple adverse effects and her disease progressed after 8 months of treatment (PMID: 33154983). | 33154983 |
| RET D898_E901del | Advanced Solid Tumor | resistant | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing RET D898_E901del were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 37535881). | 37535881 |
| KIT A502_Y503dup | gastrointestinal stromal tumor | sensitive | Cabozantinib | Preclinical - Pdx | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285). | 27777285 |
| KIT T670I | Advanced Solid Tumor | sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT T670I demonstrated sensitivity to Cometriq (Cabometyx, cabozantinib) treatment in culture, resulting in reduced cell viability (PMID: 33212994). | 33212994 |
| NRAS mutant | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Phase III | Actionable | In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression-free survival (47 vs 8 weeks, HR 0.15, p=0.0317) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386). | 27525386 |
| NRAS mutant | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Guideline | Actionable | Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RAS mutations (PMID: 31549998, PMID: 35491008; ESMO.org). | 35491008 31549998 detail... |
| HRAS mutant | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Phase III | Actionable | In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression-free survival (47 vs 8 weeks, HR 0.15, p=0.0317) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386). | 27525386 |
| HRAS mutant | thyroid gland medullary carcinoma | sensitive | Cabozantinib | Guideline | Actionable | Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RAS mutations (PMID: 31549998, PMID: 35491008; ESMO.org). | 35491008 31549998 detail... |
| KIT D816V | Advanced Solid Tumor | resistant | Cabozantinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792). | 24205792 |
| KIT W557_K558del | Advanced Solid Tumor | sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) treatment resulted in decreased viability of transformed cells expressing KIT W557_K558del in culture (PMID: 33212994). | 33212994 |
| KIT W557Lfs*5 KIT P577del KIT D820G | gastrointestinal stromal tumor | sensitive | Cabozantinib | Preclinical - Pdx | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient-derived xenograft (PDX) model harboring KIT P577del, KIT W557Lfs*5, and KIT D820G (PMID: 27777285). | 27777285 |
| RET rearrange | lung non-small cell carcinoma | sensitive | Cabozantinib | Guideline | Actionable | Cometriq (cabozantinib) is in guidelines as a first-line and subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring RET rearrangements (NCCN.org). | detail... |
| RET rearrange | lung non-small cell carcinoma | sensitive | Cabozantinib | Clinical Study | Actionable | In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 37% (7/19), with complete response in 5% (1/19) and partial response in 32% (6/19) of patients, and stable disease in 26% (5/19) of patients following Cometriq (cabozantinib) treatment (PMID: 28447912). | 28447912 |
| KIT act mut | gastrointestinal stromal tumor | sensitive | Cabozantinib | Preclinical | Actionable | In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719). | 25836719 |
| CTNNB1 mutant | endometrial cancer | predicted - sensitive | Cabozantinib | Case Reports/Case Series | Actionable | In a Phase II (NCI9322/PHL86) trial, Cometriq (Cabometyx, cabozantinib) treatment resulted in a response rate of 40% (4/10) and a 12-week progression-free survival rate of 70% (7/10) in patients with endometrial cancer harboring CTNNB1 mutations, with a median PFS of 7.6 months (PMID: 31992589; NCT01935934). | 31992589 |
| RET over exp | Advanced Solid Tumor | predicted - sensitive | Cabozantinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) treatment resulted in moderate tumor volume reduction in a cell line xenograft model of transformed cells overexpressing RET (PMID: 30446652). | 30446652 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03685448 | Phase II | Cabozantinib | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB) | Recruiting | AUS | 0 |
| NCT04022343 | Phase II | Cabozantinib | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
| NCT04631744 | Phase II | Cabozantinib | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
| NCT04876456 | Phase II | Cabozantinib | A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs | Recruiting | USA | 0 |
| NCT01835145 | Phase II | Dacarbazine Temozolomide Cabozantinib | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye | Completed | USA | CAN | 0 |
| NCT01961765 | Phase I | Cabozantinib | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
| NCT04454762 | Phase II | Cabozantinib | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function (CaboCHILD) | Unknown status | DEU | 0 |
| NCT01588821 | Phase II | Cabozantinib | Cabozantinib in Advanced Solid Malignancies | Completed | USA | 0 |
| NCT01935934 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04316182 | Phase II | Cabozantinib | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) (ACTION) | Completed | ESP | 0 |
| NCT03542877 | Phase II | Cabozantinib | Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
| NCT02885324 | Phase II | Cabozantinib | Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children | Terminated | USA | 0 |
| NCT04524208 | Phase II | Cabozantinib | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN) | Recruiting | DEU | AUT | 0 |
| NCT01896479 | FDA approved | Cabozantinib | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) | Active, not recruiting | NLD | ITA | FRA | ESP | CAN | AUS | 8 |
| NCT05168163 | Phase II | Atezolizumab + Cabozantinib Cabozantinib Atezolizumab + Lenvatinib Lenvatinib | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | Recruiting | USA | 0 |
| NCT04211337 | Phase III | Vandetanib Cabozantinib Selpercatinib | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
| NCT01709435 | Phase I | Cabozantinib | Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors | Completed | USA | CAN | 0 |
| NCT05425004 | Phase II | Cabozantinib | Cabozantinib for Patients With Recurrent or Progressive Meningioma | Recruiting | USA | 0 |
| NCT03690388 | Phase III | Cabozantinib | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 14 |
| NCT01835158 | Phase II | Cabozantinib Cabozantinib + Sunitinib | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
| NCT05012371 | Phase II | Cabozantinib Everolimus + Lenvatinib | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line Treatment of Metastatic Renal Cell Cancer | Recruiting | USA | 0 |
| NCT03612232 | Phase II | Cabozantinib | Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC) | Recruiting | DEU | 0 |
| NCT01822522 | Phase I | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus | Completed | USA | 0 |
| NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
| NCT01865747 | Phase III | Everolimus Cabozantinib | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
| NCT02315430 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT04551430 | Phase II | Cabozantinib + Ipilimumab + Nivolumab Cabozantinib | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
| NCT02036476 | Phase II | Cabozantinib | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
| NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Recruiting | USA | 1 |
| NCT04760288 | Phase III | Cabozantinib Pralsetinib Vandetanib | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) | Withdrawn | ESP | 0 |
| NCT02132598 | Phase II | Cabozantinib | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Terminated | USA | 0 |
| NCT01908426 | Phase III | Cabozantinib | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Completed | USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
| NCT04435977 | Phase II | Cabozantinib | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma (Immunocabo) | Unknown status | ITA | 0 |
| NCT03375320 | Phase III | Cabozantinib | Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT02302833 | Phase I | Cabozantinib | Cabozantinib for Malignant Pheochromocytoma | Active, not recruiting | USA | 0 |
| NCT04338269 | Phase III | Cabozantinib Atezolizumab + Cabozantinib | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
| NCT02041260 | Phase II | Cabozantinib | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | Unknown status | USA | 0 |
| NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
| NCT01811212 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Completed | USA | 0 |
| NCT01466036 | Phase II | Cabozantinib | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Completed | USA | 0 |
| NCT04522908 | Phase II | Cabozantinib | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis | Active, not recruiting | DEU | 0 |
| NCT05411081 | Phase II | Cabozantinib Atezolizumab + Cabozantinib | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | Recruiting | USA | 0 |
| NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
| NCT04071223 | Phase II | Cabozantinib + Radium Ra 223 dichloride Cabozantinib | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | Recruiting | USA | 0 |
| NCT01866293 | Phase Ib/II | Cabozantinib | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | Completed | USA | 0 |
| NCT03370718 | Phase II | Cabozantinib | Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma | Completed | USA | 0 |
| NCT04586231 | Phase III | Belzutifan + Lenvatinib Cabozantinib | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 14 |
| NCT01979393 | Phase II | Cabozantinib | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | Active, not recruiting | NLD | ITA | GBR | FRA | ESP | 0 |
| NCT04767906 | Phase II | Cabozantinib | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture) | Recruiting | DEU | 0 |
| NCT04497038 | Phase Ib/II | Cabozantinib | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | Active, not recruiting | USA | 0 |
| NCT05931393 | Phase II | Cabozantinib + Nivolumab Cabozantinib | Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) | Recruiting | USA | 0 |
| NCT01812668 | Phase I | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Completed | USA | 0 |
| NCT05092373 | Phase I | Cabozantinib Atezolizumab + Nab-paclitaxel | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Recruiting | USA | 0 |
| NCT02925234 | Phase II | Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
| NCT04205799 | Phase II | Cabozantinib | Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) | Completed | FRA | 0 |
| NCT03945773 | Phase II | Cabozantinib | Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint) | Active, not recruiting | NLD | GBR | FRA | ESP | DEU | AUT | 1 |
| NCT03428217 | Phase II | Cabozantinib Cabozantinib + Telaglenastat | CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA) | Completed | USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
| NCT03967522 | Phase II | Cabozantinib | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET) | Recruiting | FRA | 0 |
| NCT03943602 | Phase II | Cabozantinib | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) (CaboPen) | Unknown status | ITA | 0 |
| NCT04412629 | Phase II | Cabozantinib | Cabozantinib in High Grade Neuroendocrine Neoplasms | Recruiting | USA | 0 |
| NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
| NCT02761057 | Phase II | Savolitinib Cabozantinib Crizotinib Sunitinib | Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04220229 | Phase Ib/II | Cabozantinib | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Active, not recruiting | USA | 0 |
| NCT04204850 | Phase II | Cabozantinib | Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx) | Recruiting | CAN | 0 |
| NCT03755791 | Phase III | Cabozantinib Sorafenib Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) | Active, not recruiting | USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
| NCT05691478 | Phase II | Cisplatin + Doxorubicin + Methotrexate Doxorubicin + Methotrexate Cabozantinib Cabozantinib + Cisplatin + Doxorubicin + Methotrexate Cabozantinib + Doxorubicin + Methotrexate | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Suspended | USA | 0 |
| NCT05188118 | Phase I | Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
| NCT05660954 | Phase II | Cabozantinib | Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID) | Recruiting | ESP | 0 |
| NCT04134390 | Phase II | Cabozantinib | Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR) | Completed | ESP | 0 |
| NCT04300140 | Phase Ib/II | AVB-S6-500 + Cabozantinib Cabozantinib | Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma | Terminated | USA | 0 |
| NCT03964337 | Phase II | Cabozantinib | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC) | Terminated | USA | 0 |
| NCT01703065 | Phase I | Cabozantinib | Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT01834651 | Phase II | Cabozantinib | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | Completed | USA | 0 |
| NCT05265988 | Phase II | Cabozantinib | Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib (MERIDIAN) | Unknown status | ITA | 0 |
| NCT05263050 | Phase II | Cabozantinib | Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
| NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
| NCT01630590 | Phase II | Cabozantinib | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | Completed | USA | 0 |
| NCT05241561 | Phase II | Cabozantinib | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients (Cabo-POLARIS) | Not yet recruiting | FRA | 0 |
| NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
| NCT02101736 | Phase II | Cabozantinib | Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) | Completed | USA | 0 |
| NCT01582295 | Phase I | Cabozantinib | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | Completed | USA | 0 |
| NCT04066595 | Phase II | Cabozantinib | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (CabUC) | Terminated | DEU | 0 |
| NCT01755195 | Phase II | Cabozantinib | Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT03541902 | Phase II | Cabozantinib Sunitinib | Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT04511455 | Phase II | Cabozantinib | A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment | Recruiting | DEU | 0 |
| NCT04131543 | Phase II | Cabozantinib | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | Unknown status | ITA | 0 |
| NCT04310007 | Phase II | Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT02260531 | Phase II | Cabozantinib Trastuzumab | Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases | Completed | USA | 0 |
CKB BOOST